Badri Biologicals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.91 M
- Company Age 39 Year, 4 Months
- Last Filing with ROC 31 Mar 2022
- Open Charges ₹ 0.88 M
- Revenue Growth -1.82%
- Profit Growth -0.62%
- Ebitda 9.51%
- Net Worth 11.62%
- Total Assets 14.34%
About Badri Biologicals
Badri Biologicals Private Limited (BBPL) is a Private Limited Indian Non-Government Company incorporated in India on 15 October 1985 and has a history of 39 years and four months. Its registered office is in Bareilly, Uttar Pradesh, India.
The Company is engaged in the Chemicals Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.91 M.
The company currently has active open charges totaling ₹0.88 M.
Sandeep Gupta and Meenu Gupta serve as directors at the Company.
Company Details
- Location
Bareilly, Uttar Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24233UP1985PTC007468
- Company No.
007468
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Oct 1985
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Badri Biologicals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sandeep Gupta  | Director | 01-Oct-1999 | Current |
| Meenu Gupta | Additional Director | 30-Jun-2012 | Current |
Financial Performance of Badri Biologicals.
Badri Biologicals Private Limited, for the financial year ended 2020, experienced Minor drop in revenue, with a 1.82% decrease. The company also saw a slight decrease in profitability, with a 0.62% decrease in profit. The company's net worth Soared by an impressive increase of 11.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Badri Biologicals?
In 2017, Badri Biologicals had a promoter holding of 89.58% and a public holding of 10.42%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
₹0.88 M
₹0
Charges Breakdown by Lending Institutions
- Punjab National Bank : 0.05 Cr
- U.P. Financial Corporation : 0.04 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Jul 2003 | Punjab National Bank | ₹0.50 M | Open |
| 31 Mar 1989 | U.P. Financial Corporation | ₹0.38 M | Open |
How Many Employees Work at Badri Biologicals?
Badri Biologicals has a workforce of 32 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Badri Biologicals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Badri Biologicals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
